PLoS ONE (Jan 2016)

Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.

  • Mirthe E van der Valk,
  • Marie-Josée J Mangen,
  • Mirjam Severs,
  • Mike van der Have,
  • Gerard Dijkstra,
  • Ad A van Bodegraven,
  • Herma H Fidder,
  • Dirk J de Jong,
  • C Janneke van der Woude,
  • Mariëlle J L Romberg-Camps,
  • Cees H M Clemens,
  • Jeroen M Jansen,
  • Paul C van de Meeberg,
  • Nofel Mahmmod,
  • Andrea E van der Meulen-de Jong,
  • Cyriel Y Ponsioen,
  • Clemens Bolwerk,
  • J Reinoud Vermeijden,
  • Peter D Siersema,
  • Max Leenders,
  • Bas Oldenburg,
  • COIN study group and the Dutch Initiative on Crohn and Colitis

DOI
https://doi.org/10.1371/journal.pone.0142481
Journal volume & issue
Vol. 11, no. 4
p. e0142481

Abstract

Read online

With the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing hospitalization and surgery as major cost driver. We aimed to explore the evolution of IBD-related costs over two years of follow-up.In total 1,307 Crohn's disease (CD) patients and 915 ulcerative colitis (UC) patients were prospectively followed for two years by three-monthly web-based questionnaires. Changes of healthcare costs, productivity costs and out-of-pocket costs over time were assessed using mixed model analysis. Multivariable logistic regression analysis was used to identify costs drivers. In total 737 CD patients and 566 UC were included. Total costs were stable over two years of follow-up, with annual total costs of €7,835 in CD and €3,600 in UC. However, within healthcare costs, the proportion of anti-TNF therapy-related costs increased from 64% to 72% in CD (p<0.01) and from 31% to 39% in UC (p < 0.01). In contrast, the proportion of hospitalization costs decreased from 19% to 13% in CD (p<0.01), and 22% to 15% in UC (p < 0.01). Penetrating disease course predicted an increase of healthcare costs (adjusted odds ratio (adj. OR) 1.95 (95% CI 1.02-3.37) in CD and age <40 years in UC (adj. OR 4.72 (95% CI 1.61-13.86)).BD-related costs remained stable over two years. However, the proportion of anti-TNF-related healthcare costs increased, while hospitalization costs decreased. Factors associated with increased costs were penetrating disease course in CD and age <40 in UC.